It's been a challenging past three years for AbbVie ( ABBV 1.84%). The pharmaceutical leader lost U.S. patent exclusivity for ...

The fact that multiple AbbVie Inc. ( NYSE:ABBV ) insiders offloaded a considerable amount of shares over the past ...

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

AbbVie ABBV holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox ...

AbbVie's dividends add to its attractiveness at an uncertain time, adding to robust price returns over time. Click here to ...

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

AbbVie (ABBV) reached $187.12 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips. Click to read why ABBV is a Hold.

Atlantic Technological University (ATU) and AbbVie have announced a new five-year educational partnership. The agreement includes the establishment of a new ‘AbbVie Scholarship’ programme which ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian biotechnology stocks, with some brokerages calling it the largest such deal ...